Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AZD1208

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

PIM inhibitor

Related drugs:

PIM1 mutation	Diffuse Large B Cell Lymphoma	PIM1 mutation	Diffuse Large B Cell Lymphoma	venetoclax + ibrutinib + AZD1208 Sensitive: D – Preclinical venetoclax + ibrutinib + AZD1208 Sensitive : D	venetoclax + ibrutinib + AZD1208 Sensitive: D – Preclinical venetoclax + ibrutinib + AZD1208 Sensitive : D
PAI1 expression	Rectal Cancer	PAI1 expression	Rectal Cancer	AZD1208 Sensitive: D – Preclinical AZD1208 Sensitive : D	AZD1208 Sensitive: D – Preclinical AZD1208 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + AZD1208 Sensitive: D – Preclinical quizartinib + AZD1208 Sensitive : D	quizartinib + AZD1208 Sensitive: D – Preclinical quizartinib + AZD1208 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + AZD1208 Sensitive: D – Preclinical gilteritinib + AZD1208 Sensitive : D	gilteritinib + AZD1208 Sensitive: D – Preclinical gilteritinib + AZD1208 Sensitive : D